Compound information
- Natural Products
- ZC860028
- Molecular Formula
- C14H11N3O5S
- Molecular Weight
- 333.041941452 g/mol
- Structure
-
- IUPAC Name
- (1R,2R)-N-[4-(1,3-benzodioxol-5-yl)thiazol-2-yl]-2-nitro-cyclopropanecarboxamide
- InChI
- InChI=1S/C14H11N3O5S/c18-13(8-4-10(8)17(19)20)16-14-15-9(5-23-14)7-1-2-11-12(3-7)22-6-21-11/h1-3,5,8,10H,4,6H2,(H,15,16,18)/t8-,10-/m1/s1
- InChI Key
- SDSLMJOQQGAZIC-PSASIEDQSA-N
- SMILES
- O=C(Nc1nc(-c2ccc3c(c2)OCO3)cs1)[C@@H]1C[C@H]1[N+](=O)[O-]
- Source
- ZINC000044311514
Warheads
- Cyclopropane
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 23 | Ring Count | 4 |
| Heteroatom Count | 9 | Rotatable Bond Count | 4 |
| Hydrogen Bond Acceptor Count | 7 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 103.59 Å2 | LogP | 2.635 |
| LogS | -3.941 | LogD | 2.952 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.031 | Pgp substrate | 0.003 |
| HIA | 0.959 | F20 % | 0.967 |
| F30 % | 0.671 | Caco-2 | -4.994 |
| MDCK | -4.843 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.33 | PPB | 91.641 |
| VD | 0.591 | Fu | 1.15 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.997 | CYP1A2 substrate | 0.674 |
| CYP2A6 substrate | 0.586 | CYP2B6 substrate | 0.618 |
| CYP2C19 inhibitor | 0.153 | CYP2C19 substrate | 0.753 |
| CYP2C8 substrate | 0.657 | CYP2C9 inhibitor | 0.135 |
| CYP2C9 substrate | 1.0 | CYP2D6 inhibitor | 0.025 |
| CYP2D6 substrate | 0.518 | CYP2E1 substrate | 0.918 |
| CYP3A4 inhibitor | 0.938 | CYP3A4 substrate | 1.0 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.332 | CL | 10.962 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.015 | Hepatotoxicity | 0.562 |
| Mutagenicity | 0.927 | Rat Oral Acute Toxicity | 0.249 |
| FDAMDD | 0.204 | Skin Sensitization | 0.475 |
| Carcinogenicity | 0.819 | Eye Corrosion | 0.003 |
| Eye Irritation | 0.32 | Respiratory Toxicity | 0.987 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | -0.003 | IGC50 | 3.765 |
| LC50FM | 3.678 | LC50DM | 5.197 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.817 | NR-AR-LBD | 0.512 |
| NR-AhR | 0.944 | NR-Aromatase | 0.029 |
| NR-ER | 0.566 | NR-ER-LBD | 0.491 |
| NR-PPAR-gamma | 0.703 | SR-ARE | 0.816 |
| SR-ATAD5 | 0.832 | SR-HSE | 0.345 |
| SR-MMP | 0.8 | SR-p53 | 0.557 |
Similar covalent drugs
No similar covalent drugs found for this compound.